To Characterize the Safety and Tolerability of Eculizumab in Two Japanese aHUS Patients

N/ACompletedNCT01755429

Alexion Pharmaceuticals, Inc.2 enrolled

Overview

This protocol is intended to formally collect data on the treatment of aHUS with eculizumab in Japanese patients.

Study Type

OBSERVATIONAL

Enrollment

Conditions

ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patient and/or legal guardian must be willing and able to give written informed consent and id the patient is not an adult and able to read and write, the patient is willing to give written informed assent 2. Eculizumab treatment initiated as personal importation for aHUS in 201 Exclusion Criteria: Not Applicable

Locations (2)

Shinshu University School of Medicine

Matsumoto, Japan

Tokyo Medical and Dental University

Tokyo, Japan

Outcomes

Primary Outcomes

Change in platelet count from baseline

Time frame: 26 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.